A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Launched by ACLARIS THERAPEUTICS, INC. · Apr 5, 2018

Keywords

ClinConnect Summary

This is an open-label study designed to evaluate the safety and efficacy of ATI-50002 Topical Solution in male and female subjects with androgenetic alopecia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a clinical diagnosis of androgenetic alopecia.
• • Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length on their balding spot.
• • Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the center of the identified target area.
• • Subjects must agree to maintain the same hair style and hair care regimen during the study.
• Exclusion Criteria:
• • Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.
• • Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss on the treatment area, due to disease, injury or medical therapy.
• • Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments or efficacy or safety.